The first Amedisys trade was made in Q3 2020.
Since then Ray Dalio bought shares seven more times and sold shares on eleven occasions. The investor completely sold their stake between Q4 2023 and Q1 2025.
Avg closing price
Price range
Sold -3.69 Thousand shares
Q1 2025
Avg closing price
$92.20
Price range
$90.44
-
$92.90
Sold 71.3% shares (-9.14 Thousand shares)
Q4 2024
Avg closing price
$91.69
Price range
$83.52
-
$97.71
Sold 52.5% shares (-14.2 Thousand shares)
Q3 2024
Avg closing price
$97.57
Price range
$96.51
-
$98.45
Sold 8.8% shares (-2.6 Thousand shares)
Q2 2024
Avg closing price
$92.79
Price range
$90.40
-
$96.77
Sold 14.5% shares (-5.04 Thousand shares)
Q1 2024
Avg closing price
$93.71
Price range
$92.15
-
$95.24
Sold 9.5% shares (-3.63 Thousand shares)
Q4 2023
Avg closing price
$93.40
Price range
$91.15
-
$95.90
Increased shares by 9.1% (+3.18 Thousand shares)
Q3 2023
Avg closing price
$92.41
Price range
$89.84
-
$94.08
Sold 10.5% shares (-4.13 Thousand shares)
Q2 2023
Avg closing price
$82.04
Price range
$73.99
-
$92.60
Sold 2.4% shares (-980 shares)
Q1 2023
Avg closing price
$86.52
Price range
$69.79
-
$100.33
Sold 21.4% shares (-11 Thousand shares)
Q4 2022
Avg closing price
$90.16
Price range
$80.12
-
$105.34
Sold 0.4% shares (-184 shares)
Q3 2022
Avg closing price
$119.25
Price range
$96.79
-
$131.14
Increased shares by 7.0% (+3.36 Thousand shares)
Q2 2022
Avg closing price
$127.76
Price range
$105.12
-
$173.85
Increased shares by 35.0% (+12.4 Thousand shares)
Q1 2022
Avg closing price
$149.40
Price range
$124.79
-
$178.09
Increased shares by 4.4% (+1.5 Thousand shares)
Q4 2021
Avg closing price
$160.71
Price range
$136.32
-
$184.41
Sold 3.5% shares (-1.23 Thousand shares)
Q3 2021
Avg closing price
$207.88
Price range
$149.10
-
$270.32
Increased shares by 84.8% (+16.2 Thousand shares)
Q2 2021
Avg closing price
$262.37
Price range
$238.97
-
$288.50
Increased shares by 1.3% (+246 shares)
Q1 2021
Avg closing price
$282.02
Price range
$236.62
-
$314.16
Increased shares by 138.3% (+10.9 Thousand shares)
Q4 2020